Transcode Therapeutics Stock Current Asset
RNAZ Stock | USD 0.38 0.04 11.56% |
Transcode Therapeutics fundamentals help investors to digest information that contributes to Transcode Therapeutics' financial success or failures. It also enables traders to predict the movement of Transcode Stock. The fundamental analysis module provides a way to measure Transcode Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Transcode Therapeutics stock.
At this time, Transcode Therapeutics' Total Current Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 750 K in 2024, whereas Other Current Assets are likely to drop slightly above 1.5 M in 2024. Transcode | Current Asset |
Transcode Therapeutics Company Current Asset Analysis
Transcode Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Transcode Current Asset Historical Pattern
Today, most investors in Transcode Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Transcode Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Transcode Therapeutics current asset as a starting point in their analysis.
Transcode Therapeutics Current Asset |
Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition |
Transcode Net Tangible Assets
Net Tangible Assets |
|
In accordance with the recently published financial statements, Transcode Therapeutics has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
Transcode Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transcode Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Transcode Therapeutics could also be used in its relative valuation, which is a method of valuing Transcode Therapeutics by comparing valuation metrics of similar companies.Transcode Therapeutics is currently under evaluation in current asset category among its peers.
Transcode Fundamentals
Return On Equity | -10.49 | ||||
Return On Asset | -2.08 | ||||
Current Valuation | 4.08 M | ||||
Shares Outstanding | 17.27 M | ||||
Shares Owned By Insiders | 0.01 % | ||||
Shares Owned By Institutions | 1.99 % | ||||
Number Of Shares Shorted | 743.58 K | ||||
Price To Book | 3.51 X | ||||
EBITDA | (17.97 M) | ||||
Net Income | (18.55 M) | ||||
Cash And Equivalents | 13.45 M | ||||
Cash Per Share | 1.04 X | ||||
Total Debt | 450.57 K | ||||
Current Ratio | 8.06 X | ||||
Book Value Per Share | 2.62 X | ||||
Cash Flow From Operations | (18.07 M) | ||||
Short Ratio | 0.50 X | ||||
Earnings Per Share | 168.84 X | ||||
Target Price | 3.0 | ||||
Number Of Employees | 10 | ||||
Beta | 0.65 | ||||
Market Capitalization | 5.8 M | ||||
Total Asset | 5.17 M | ||||
Retained Earnings | (46.42 M) | ||||
Working Capital | 964.85 K | ||||
Net Asset | 5.17 M |
About Transcode Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transcode Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.